ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1889

Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1710

Remote Rheumapalooza: Reboot of a Foundational Rheumatology Curriculum for Pre-Clinical Medical Students in the Era of Virtual Learning

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1672

Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1791

Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1842

Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1786

Reproductive Health Outcomes in Women with RA and PsA

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1554

Response to Tocilizumab in Large Vessel Vasculitis According to the Extent of Baseline 18F-FDG Vascular Uptake

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1586

Rheum Service: Comprehensive Virtual Care During COVID-19

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1759

Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1761

Rheumatoid Arthritis Inpatient Mortality: An Analysis of the National Inpatient Sample

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1694

Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1775

Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1825

Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1947

Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1938

Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].